Boostimmune

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a memorandum of understanding (MOU) with South Korea-headquartered Boostimmune. This collaboration focuses on research and discovery services related to Boostimmune’s innovative pipelines. Under this agreement, WuXi Bio will serve as Boostimmune’s exclusive research and development service…